HFE基因多态性检测判断慢性丙型肝炎患者疾病活动的价值*

doi:10.3969/j.issn.1672-5069.2020.02.012

Abstract

Abstract: Objective The aim of this study was to investigate the implication of HFE, a genetic hemochromatosis candidate gene, polymorphism in individuals with hepatitis C viral infection. Methods 257 individuals with hepatitis C infection (131 with hepatitis C infection and 126 with chronic hepatitis C, CHC) were enrolled in our hospital between November 2016 and November 2018, and serum ferritin was assayed. The distribution of two polymorphic loci, e.g. rs2071303 and rs9366637, were detected. Results Serum ferritin level in individuals with hepatitis C infection were (97.5±4.1)μg/L, significantly lower than 【(202.1±24.5)μg/L,P＜0.05】 in patients with CHC, serum ALT level was (34.0±4.5)U/L, significantly lower than 【(88.4±5.6)U/L, P＜0.05】, AST level was (37.5±4.2)U/L, much lower than 【(70.0±5.4)U/L, P＜0.05】 in patients with CHC; the frequency of non-Ⅰb in individuals with HCV infection was 29.8%, much highpolymorphism; Ferritin; Active disease than 13.5%(P＜0.05), and of mixed was 9.1%, significantly lower than 21.4%(P＜0.05) in patients with CHC; serum SF level in infected persons with GG genotype at rs2071303 locus was (97.6±4.2) μg/L, significantly lower than [(199.5±45.4) μg/L, P<0.05], in with GA genotype was (97.6±4.1) μg/L, significantly lower than [(207.5±34.7) μg/L, P<0.05], in with AA genotype was (96.7±3.7) μg/L, significantly lower than [(198.0±44.8) μg/L, P<0.05] in patients with CHC, and SF level in infected persons with TT genotype at rs9366637 locus was (97.4±4.0) μg/L, significantly lower than [(206.4 ±35.6) μg/L, P<0.05], in with TC genotype was (97.2±4.0) μg/L, significantly lower than [(208.5±34.0) μg/L, P<0.05], in with CC genotype was (99.1±4.5) μg/L, significantly lower than [(178.5±58.6) μg/L, P<0.05] in patients with CHC; the frequency of AA genotype of rs2071303 in infected persons was 13.7%, significantly lower than 21.4% in patients with CHC (P<0.05), and the frequency of haplotype AC was 3.1%, significantly lower than 8.3% in patients with CHC (P<0.05). Conclusion HFE gene polymorphism is closely related to the active disease in individuals with chronic hepatitis C viral infection, which warrants further investigation.

Key words: Hepatitis C, Genetic hemochromatosis candidate gene, HFE, Gene

Liu Yijun, Duan Shuxin , You Chunfang, et al. Implication of HFE gene polymorphism in individuals with hepatitis C viral infection[J]. Journal of Practical Hepatology, 2020, 23(2): 195-198.

References

[1] 汤伟亮, 谢青. 基因3型丙型肝炎病毒感染及其抗病毒治疗. 实用肝脏病杂志, 2016, 19(4):394-397.
[2] Messina JP , Humphreys I , Flaxman A , et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology, 2015, 61(1):77-87.
[3] Kandeel A , Genedy M , El-Refai S , et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int, 2017, 37(1):45-53.
[4] Lee SY, Zhu J, Salzberg AC, et al. Analysis of single nucleotide variants of HFE gene and association to survival in The Cancer Genome Atlas GBM data. Plos One, 2017, 12(3):1-18.
[5] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2015年更新版.实用肝脏病杂志,2016,19(4):IX-XXVI.
[6] Kandeel A , Genedy M , El-Refai S , et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int, 2017, 37(1):45-53.
[7] Kuniholm MH , Jung M , Everhart JE , et al. Prevalence of hepatitis C virus infection in US hispanic/latino adults: results from the NHANES 2007-2010 and HCHS/SOL studies. J Infect Dis, 2015, 209(10):1585-1590.
[8] 刘茵, 邹霞, 徐勇,等. 社区美沙酮维持治疗新入组者HCV感染率变化趋势及危险因素. 中华疾病控制杂志, 2017, 21(1):35-39.
[9] Uchino K, Tateishi R, Fujiwara N, et al. Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. Hepatol Res, 2016, 46(4):259-268.
[10] Nanba S, Ikeda F, Baba N, et al. Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C. J Clin Pathol, 2016, 69(3):226-233.
[11] Hamdirozé H, Beaumontepinette MP , Benali Z, et al. Rare HFE variants are the most frequent cause of hemochromatosis in non-c282y homozygous patients with hemochromatosis. Am J Hematol, 2016, 91(12):1202-1205.
[12] Adams P, Altes A , Brissot P , et al. Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatol Int, 2018, 12(2):83-86.
[13] Subramaniam VN . The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data. Genet Med, 2016, 18(6):618-626.
[14] Frederico SV, Reis H, Zilma N , et al. Novel method probe-based real-time PCR to detect 2 single-nucleotide polymorphisms close to each other: HFE hemochromatosis gene model. Appl Immunohisto M M, 2016, 24(9):673-678.
[15] TÖndury P, Zimmermann A , Nielsen P , et al. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassemic patients. Brit J Haematol, 2015, 101(3):413-415.
[16] Latour C, Bessonfournier C, Meynard D, et al. Differing impact of the deletion of hemochromatosis-associated molecules HFE and transferrin receptor-2 on the iron phenotype of mice lacking bone morphogenetic protein 6 or hemojuvelin. Hepatology, 2016, 63(1):126-137.
[17] 程诗佳, 王旭, 崔久嵬. 微量元素铁与肿瘤发生及发展的关系. 中华肿瘤防治杂志, 2016, 23(24):1645-1651.
[18] Garewal G, Das R, Ahluwalia J, et al. Prevalence of the H63D mutation of the HFE in north India: its presence does not cause iron overload in beta thalassemia trait. Eur J Haematol, 2015, 74(4):333-336.
[19] Milman N, Koefoed P, Pedersen P, et al. Frequency of the HFE C282Y and H63D mutations in Danish patients with clinical haemochromatosis initially diagnosed by phenotypic methods. Eur J Haematol, 2015, 71(6):403-407.
[20] 罗碧芬, 魏来. 丙型肝炎研究领域2016年新进展. 中华肝脏病杂志, 2017, 25(3):175-180.

Implication of HFE gene polymorphism in individuals with hepatitis C viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Xiaowei, Zhong Rui. Short-term efficacy and tolerance ofsofosbuvir/velpatasvir and ribavirin combination in the treatment of hepatitis C patients with genotype 2 or 3 infection [J]. Journal of Practical Hepatology, 2020, 23(2): 191-194.
[2]	Zhang Jianzhen, Zeng Chunyan, Zhang Chunlan, et al. A real-world study: Efficacy of combination of sofebuvir and daclatasvir in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2020, 23(1): 30-33.
[3]	Liu Jian, Zhu Fengfa, Tang Juan. Ultrasonographic and biochemical features of patients with non-alcoholic heterogeneous fatty liver [J]. Journal of Practical Hepatology, 2020, 23(1): 42-45.
[4]	Zhang Bing, Xie Xuejun. Correlation of polymorphisms of CTLA-4 and PNPLA3 genes tothe pathogenesis of alcoholic cirrhosis in human [J]. Journal of Practical Hepatology, 2020, 23(1): 86-89.
[5]	Huang Hanjun, Lu Fengrong, Zhang Can. Changes of apparent diffusion coefficient from MRI and serum vitamin D levels in predicting hepatic fibrosis in patients with hepatitis C [J]. Journal of Practical Hepatology, 2020, 23(1): 143-144.
[6]	. Guidelines for the prevention and treatment of hepatitis C (2019 version) [J]. Journal of Practical Hepatology, 2020, 23(1): 185-204.
[7]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[8]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[9]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[10]	Jin Zhen, Zhou Xiaochun, Ma Hongxia.. Paravertebral block combined with general anesthesia inhibit inflammatory response and improve rehabilitation of patients underwent hepatic hemangioma resection [J]. Journal of Practical Hepatology, 2019, 22(6): 908-911.
[11]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[12]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[13]	Cui Faqiang, Li Tao, Wang Zheng, et al. A pilot study on cetuximab and KRAS gene mutation in treatment of patients with primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 565-568.
[14]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[15]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.